Clinical trials: Resistant Major Depressive Disorder
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Major Depressive Disorder
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated.
- Trial name
- NCT01582945
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major, Metabolic Syndrome X
Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome
The goal of this study is to begin to test whether or not pioglitazone, an FDA approved medication used to treat high blood sugar, may be safe and effective in treating Major Depressive Disorder (MDD) in patients with comorbid…
- Trial name
- NCT00671515
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Joseph Calabrese, MD
Major Depressive Disorder
Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females
The investigators propose to determine if 8 weeks of dietary augmentation with oral 5g creatine monohydrate daily and 100 mg of 5-hydroxytryptophan (5-HTP) twice daily reduces hypoxia-related depressive symptoms measured by the…
- Trial name
- NCT02922725
- Testing
- 5-hydroxytryptophan and Creatine
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Brent Michael Kious, MD, PhD
Treatment Resistant Depression
Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression
This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of oral CERC-501 for treating patients with treatment resistant depression who are taking an antidepressant that is not working for them.
- Trial name
- RAPID KOR (NCT01913535)
- Testing
- CERC-501
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Massachusetts General Hospital
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Treatment-Resistant Depression Registry
This registry will collect information about patients with treatment-resistant depression (TRD) who are currently in a major depressive episode.
- Trial name
- NCT00320372
- Where
- 55 sites in United States
- Volunteers
- 795 people
- Sponsor
- Cyberonics, Inc.
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder
5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females
The investigators hypothesize that the administration of two widely available, naturally occurring dietary supplements, 5 hydroxytryptophan and creatine monohydrate, will reduce the severity of depression in individuals exposed…
- Trial name
- NCT02356107
- Testing
- 5-hydroxytryptophan and Creatine monohydrate
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Perry Renshaw